<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01518166</url>
  </required_header>
  <id_info>
    <org_study_id>NN2211-1608</org_study_id>
    <secondary_id>2006-000175-15</secondary_id>
    <nct_id>NCT01518166</nct_id>
  </id_info>
  <brief_title>Effect of Liraglutide on Gastrointestinal Absorption of Several Drugs and Potential Influence of Liraglutide on Intragastric pH</brief_title>
  <official_title>A Two-way Cross-over, Placebo-controlled Interaction Trial in Two Parts (in Healthy Subjects), Studying Liraglutide's Potential Influence on the Absorption Pharmacokinetics of Lisinopril, Atorvastatin, Griseofulvin and Digoxin, and Liraglutide's Potential Influence on Intragastric pH</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novo Nordisk A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The trial is conducted in Europe. The aim of the trial is to investigate if there is any drug
      to drug interaction between liraglutide and atorvastatin (Lipitor®), lisinopril (Zestril®),
      griseofulvin and digoxin (Lanoxin®).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2006</start_date>
  <completion_date type="Actual">April 2007</completion_date>
  <primary_completion_date type="Actual">April 2007</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the curve of atorvastatin</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the curve of lisinopril</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the curve of griseofulvin</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the curve of digoxin</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area under the curve of liraglutide</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax, maximum concentration</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>tmax, time to reach Cmax</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal elimination rate constant</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intragastric pH</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">70</enrollment>
  <condition>Diabetes</condition>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Trial period A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Trial period B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>liraglutide</intervention_name>
    <description>Administered as a subcutaneous injection. Initial dose 0.6 mg daily, adjusted to 1.2 mg daily in week 2 and escalated to 1.8 mg daily in week 3</description>
    <arm_group_label>Trial period A</arm_group_label>
    <arm_group_label>Trial period B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Administered as a subcutaneous injection. Given as daily volume of 100 mcl, 200 mcl and 300 mcl respectively</description>
    <arm_group_label>Trial period A</arm_group_label>
    <arm_group_label>Trial period B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>atorvastatin</intervention_name>
    <description>One single dose of 40 mg. Tablet</description>
    <arm_group_label>Trial period A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lisinopril</intervention_name>
    <description>One single dose of 20 mg. Tablet</description>
    <arm_group_label>Trial period A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>griseofulvin</intervention_name>
    <description>One single dose of 500 mg. Tablet</description>
    <arm_group_label>Trial period B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>digoxin</intervention_name>
    <description>One single dose of 1 mg. Tablet</description>
    <arm_group_label>Trial period B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female subjects if using adequate anti-contraception or is sterile

          -  Body Mass Index (BMI) of 18-30 kg/m^2 (both inclusive)

          -  Good general health as judged by the investigator, based on medical history, physical
             examination including 12-lead ECG (electrocardiogram), vital signs and blood and
             urinary laboratory assessments

          -  Willing and capable to self-administer a subcutaneous injection

        Exclusion Criteria:

          -  History of any clinically significant renal, hepatic, cardiovascular, pulmonary,
             gastrointestinal, metabolic, endocrine, haematological, neurological, psychiatric
             disease or other major disorders that may interfere with the objectives of the trial,
             as judged by the investigator

          -  Impaired renal function

          -  Blood pressure and heart rate in supine position outside the ranges 90-140 mmHg
             systolic, 50-90 mmHg diastolic and heart rate 40-100 beats/min

          -  Any clinically significant abnormal ECG

          -  Active hepatitis B and/or active hepatitis C

          -  Positive HIV (human immunodeficiency virus) antibodies

          -  Known or suspected allergy to trial product(s) or related products

          -  Use of any prescription or non-prescription medication except for paracetamol, nasal
             spray or drops for nasal congestion, and vitamins within 2 weeks prior to first dosing
             and during the entire trial period

          -  History of alcoholism or drug abuse during the last 12 months

          -  Smoking of more than 10 cigarettes per day, or the equivalent for other tobacco
             products

          -  Habitual excessive consumption of methylxanthine-containing beverages and foods
             (coffee, tea, soft drinks such as cola, chocolate) as judged by the Investigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Global Clinical Registry (GCR, 1452)</last_name>
    <role>Study Director</role>
    <affiliation>Novo Nordisk A/S</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Uppsala</city>
        <zip>75323</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <link>
    <url>http://novonordisk-trials.com</url>
    <description>Clinical Trials at Novo Nordisk</description>
  </link>
  <results_reference>
    <citation>Malm-Erjefält M, Ekblom M, Vouis J, Zdravkovic M, Lennernäs H. Effect on the Gastrointestinal Absorption of Drugs from Different Classes in the Biopharmaceutics Classification System, When Treating with Liraglutide. Mol Pharm. 2015 Nov 2;12(11):4166-73. doi: 10.1021/acs.molpharmaceut.5b00278. Epub 2015 Oct 12.</citation>
    <PMID>26426736</PMID>
  </results_reference>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 17, 2012</study_first_submitted>
  <study_first_submitted_qc>January 21, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 25, 2012</study_first_posted>
  <last_update_submitted>January 24, 2017</last_update_submitted>
  <last_update_submitted_qc>January 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 25, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atorvastatin Calcium</mesh_term>
    <mesh_term>Digoxin</mesh_term>
    <mesh_term>Lisinopril</mesh_term>
    <mesh_term>Liraglutide</mesh_term>
    <mesh_term>Griseofulvin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

